Table 1.

Summary of patient characteristics for the NEO study and I-SPY validation set

Characteristics	NEO cohort (50)	NEO cohort PT-TM pairs (23)	p value	I-SPY 1 PT-T2 pairs (36)	p value
Median age at diagnosis	50.8	50.1	0.8	47
Tumour grade			0.52		0.58
1	0 (0%)	0 (0%)		1 (3%)
2	22 (44%)	12 (52%)		20 (55%)
3	28 (56%)	11 (48%)		15 (42%)
Hormone receptor status			0.24		0.66
Positive	23 (46%)	14 (61%)		24 (67%)
Negative	27 (54%)	9 (39%)		12 (33%)
HER2 status			0.87		0.64
Positive	10 (20%)	5 (22%)		6 (17%)
Negative	40 (80%)	18 (78%)		30 (83%)